Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Late respiratory effects of cancer treatment.

Harris C, Sander CR.

Curr Opin Support Palliat Care. 2017 Sep;11(3):197-204. doi: 10.1097/SPC.0000000000000286. Review.


British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.

Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. Review.


Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.

Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.


Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Pathan AA, Minassian AM, Sander CR, Rowland R, Porter DW, Poulton ID, Hill AV, Fletcher HA, McShane H.

Vaccine. 2012 Aug 17;30(38):5616-24. doi: 10.1016/j.vaccine.2012.06.084. Epub 2012 Jul 10.


A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults.

Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, Poyntz H, Hamill M, Griffiths K, Sander CR, Ambrozak DR, Price DA, Hill BJ, Casazza JP, Douek DC, Koup RA, Roederer M, Winston A, Ross J, Sherrard J, Rooney G, Williams N, Lawrie AM, Fletcher HA, Pathan AA, McShane H.

BMJ Open. 2011 Nov 14;1(2):e000223. doi: 10.1136/bmjopen-2011-000223. Print 2011.


Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.

Griffiths KL, Pathan AA, Minassian AM, Sander CR, Beveridge NE, Hill AV, Fletcher HA, McShane H.

PLoS One. 2011;6(8):e23463. doi: 10.1371/journal.pone.0023463. Epub 2011 Aug 26.


Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, Hill AV, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2010 Jul;17(7):1066-73. doi: 10.1128/CVI.00047-10. Epub 2010 May 19. Erratum in: Clin Vaccine Immunol. 2011 Apr;18(4):696.


Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.

Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Hill AV, McShane H.

PLoS One. 2009 Jun 16;4(6):e5934. doi: 10.1371/journal.pone.0005934. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/ec8cc565-bf24-4898-b7ba-6e0423d5809f.


Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H.

Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33. doi: 10.1164/rccm.200809-1486OC. Epub 2009 Jan 16.


Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.

Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, Hill AV, McShane H, Kaufmann SH.

Infect Immun. 2009 Feb;77(2):622-31. doi: 10.1128/IAI.00685-08. Epub 2008 Dec 8. Erratum in: Infect Immun. 2011 May;79(5):2133.


A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Beveridge NE, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, Sander CR, Whelan KT, Dockrell HM, Hill AV, Hanekom WA, McShane H.

Tuberculosis (Edinb). 2008 Nov;88(6):631-40. doi: 10.1016/ Epub 2008 Sep 17.


Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AV, McShane H.

Vaccine. 2008 Sep 26;26(41):5269-75. doi: 10.1016/j.vaccine.2008.07.040. Epub 2008 Aug 3.


Interstitial lung disease in systemic sclerosis: a simple staging system.

Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU.

Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi: 10.1164/rccm.200706-877OC. Epub 2008 Mar 27.


Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H.

PLoS One. 2007 Oct 24;2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.


Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, Roederer M, Koup RA, Douek DC, Hill AV, McShane H.

Eur J Immunol. 2007 Nov;37(11):3089-100. Erratum in: Eur J Immunol. 2011 May;41(5):1501.


Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. Epub 2005 Jan 21. Review.


Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.


Supplemental Content

Loading ...
Support Center